Allergan Stock Price, News & Analysis (NYSE:AGN)

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan declared a quarterly dividend on Friday, July 19th. Stockholders of record on Tuesday, August 13th will be paid a dividend of $0.74 per share on Friday, September 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.73%. The ex-dividend date is Monday, August 12th. View Allergan's Dividend History.

Allergan declared that its board has approved a stock repurchase plan on Tuesday, January 29th 2019, which allows the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 4.1% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board of directors believes its shares are undervalued.

Allergan plc (NYSE:AGN) announced its quarterly earnings results on Tuesday, August, 6th. The company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.34 by $0.04. The firm had revenue of $4.09 billion for the quarter, compared to analyst estimates of $3.93 billion. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The company's revenue was down .8% on a year-over-year basis. During the same period last year, the firm earned $4.42 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Allergan.

Allergan updated its FY19 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of >$16.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.74. The company issued revenue guidance of 15.4-15.6 billion, compared to the consensus revenue estimate of $15.32 billion.

21 brokerages have issued 12 month price targets for Allergan's shares. Their forecasts range from $144.95 to $255.00. On average, they expect Allergan's stock price to reach $179.15 in the next year. This suggests a possible upside of 4.9% from the stock's current price. View Analyst Price Targets for Allergan.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 15 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

Media coverage about AGN stock has been trending very negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Allergan earned a news sentiment score of -3.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Allergan.

Allergan saw a increase in short interest in September. As of September 30th, there was short interest totalling 10,330,000 shares, an increase of 8.9% from the August 30th total of 9,490,000 shares. Based on an average daily trading volume, of 3,600,000 shares, the short-interest ratio is presently 2.9 days. Approximately 3.2% of the company's shares are short sold. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Bayer (BAYRY) and Zoetis (ZTS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan's stock is owned by a number of of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.54%), Metropolis Capital Ltd (0.05%), Confluence Investment Management LLC (0.05%), State of Alaska Department of Revenue (0.02%), Havens Advisors LLC (0.02%) and Alpine Group USVI LLC (0.01%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Metropolis Capital Ltd, Confluence Investment Management LLC, Gateway Investment Advisers LLC, Nelson Van Denburg & Campbell Wealth Management Group LLC, Gofen & Glossberg LLC IL, Welch & Forbes LLC, Arden Trust Co and Gibraltar Capital Management Inc.. View Insider Buying and Selling for Allergan.

AGN stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Alpine Group USVI LLC, Alpine Group USVI LLC, Havens Advisors LLC, State of Alaska Department of Revenue, Cerebellum GP LLC, Cerebellum GP LLC and Wealthfront Advisers LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $170.84.

Allergan has a market capitalization of $56.04 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]